<DOC>
	<DOCNO>NCT01860794</DOCNO>
	<brief_summary>The purpose clinical trial evaluate safety tolerability Fetal Mesencephalic Dopamine Neuronal Precursor Cells treatment Patients Parkinson 's disease .</brief_summary>
	<brief_title>Evaluation Safety Tolerability Fetal Mesencephalic Dopamine Neuronal Precursor Cells Parkinson 's Disease</brief_title>
	<detailed_description>This study phase I/II clinical trial accessible involved study conduct Bundang CHA hospital . The progress clinical trail report evaluated Data monitoring committee enrolment next human subject .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Parkinsonian Disorders</mesh_term>
	<mesh_term>Dopamine</mesh_term>
	<criteria>1 . Female patient idiopathic primary Parkinson 's disease 2 . Hoehn Yare ( HY ) stage III IV 3. 33 % improvement Part III UPDRS score one injection levodopa morning 4 . Patients age less 70 5 . Great decrease dopamine uptake putamen , particularly posterior part , Positron emission tomograph ( PET ) surgery 1 . Atypical secondary parkinsonism 2 . Medical history severe depression Beck Depression Inventory ( BDI ) score great 30 3 . Psychological disorder ( illusion , delusion , schizophrenia ) 4 . Dementia KMMSE ( Korean minimental state examination ) score less 24 5 . Epilepsy 6 . Medial history brain surgery 7 . Medical history brain diseases 8 . Hemorrhagic tendency 9 . Severe internal disease poor general condition , hypertension , chronic respiratory disease , ischemic heart disease , cancer 10 . Experience participate clinical trial within 30 day 11 . Female patient chance get pregnant clinical trial use approve birth control 12 . Pregnant lactate woman 13 . Patients consider eligible participate clinical trial</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2013</verification_date>
</DOC>